Copy to clipboard 
Loci Orthopaedics was a new patent for the bespoke implantation set for its InDx CMC (carpometacarpal) implant system.
In addition to the recently granted patent, other granted patents include the core design of its implant technology (US 10,265,186), the use of the same biomechanical design in additional joints (US 11,213,401), discrete elements of the implant design (US 10,799,365) and the use of the design post trapeziectomy (US 11,399,950).
In addition, the company has recently received notification that the USPTO intends to grant a patent for conversion of the design from a hemi-arthroplasty to a total arthroplasty. This brings to a total of six individual patents the company has now been granted for its implant system to treat thumb base joint arthritis, and reportedly makes Loci Orthopaedics the holder of one of the largest CMC joint implant patent portfolios.
Loci Orthopaedics was recently granted over $8 million from the European Union government to advance and accelerate the development of the InDx Implant, reflecting the major unmet clinical need and significant market opportunity.
Commenting on the recent patent granting, CEO and Co-Founder of Loci Orthopaedics, Brendan Boland, said, “The company focuses on evidence-based design and providing unique design solutions for customers and patients. This is reflected in the company’s rapidly growing patent portfolio. The company now holds one of the most significant IP portfolios of implant designs for the thumb base joint.”
Commenting on potential clinical impact of the company’s patents, CTO and Co-Founder of Loci Orthopaedics, Gerry Clarke, said, “The company has granted patents not only for a novel and exciting treatment option for this condition, but also for the bespoke tool set to facilitate the optimal implantation. In addition, the company has granted patents for several different stages of this common and debilitating condition, opening a whole new potential treatment option spectrum.”
Source: Loci Orthopaedics
Loci Orthopaedics was a new patent for the bespoke implantation set for its InDx CMC (carpometacarpal) implant system.
In addition to the recently granted patent, other granted patents include the core design of its implant technology (US 10,265,186), the use of the same biomechanical design in additional joints (US 11,213,401), discrete...
Loci Orthopaedics was a new patent for the bespoke implantation set for its InDx CMC (carpometacarpal) implant system.
In addition to the recently granted patent, other granted patents include the core design of its implant technology (US 10,265,186), the use of the same biomechanical design in additional joints (US 11,213,401), discrete elements of the implant design (US 10,799,365) and the use of the design post trapeziectomy (US 11,399,950).
In addition, the company has recently received notification that the USPTO intends to grant a patent for conversion of the design from a hemi-arthroplasty to a total arthroplasty. This brings to a total of six individual patents the company has now been granted for its implant system to treat thumb base joint arthritis, and reportedly makes Loci Orthopaedics the holder of one of the largest CMC joint implant patent portfolios.
Loci Orthopaedics was recently granted over $8 million from the European Union government to advance and accelerate the development of the InDx Implant, reflecting the major unmet clinical need and significant market opportunity.
Commenting on the recent patent granting, CEO and Co-Founder of Loci Orthopaedics, Brendan Boland, said, “The company focuses on evidence-based design and providing unique design solutions for customers and patients. This is reflected in the company’s rapidly growing patent portfolio. The company now holds one of the most significant IP portfolios of implant designs for the thumb base joint.”
Commenting on potential clinical impact of the company’s patents, CTO and Co-Founder of Loci Orthopaedics, Gerry Clarke, said, “The company has granted patents not only for a novel and exciting treatment option for this condition, but also for the bespoke tool set to facilitate the optimal implantation. In addition, the company has granted patents for several different stages of this common and debilitating condition, opening a whole new potential treatment option spectrum.”
Source: Loci Orthopaedics
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
